Narrator: This is Science Today. Herceptin, a breast cancer treatment that triggered an era of targeted therapies, is in its fifth year of use and continues to be tested in dozens of clinical trials nationwide. Dr. Hope Rugo, co-director of the Breast Oncology Clinical Trials Program at the University of California, San Francisco, has enrolled patients in a current national trial.
Rugo: It's an interesting trial because one group of women will get chemotherapy and the other two groups of women will get chemotherapy with Herceptin. One group gets Herceptin starting halfway through and continuing with chemotherapy for a year and the other group of women get the Herceptin after the end of chemotherapy for a year.
Narrator: The goal is to unlock future potential treatment benefits for women in various stages of breast cancer.
Rugo: We're very excited about the use of Herceptin in this setting and if the trial is in fact positive, that's going to lead to really a revolutionized approach to breast cancer treatment.
Narrator: For Science Today, I'm Larissa Branin.